目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T75422 | |||
Monoamine oxidase 是一种由不同多肽组成的酶。Monoamine oxidase 通过产生过氧化氢催化大脑和外周组织中多种生物胺氧化脱氨。Monoamine oxidase 在维持突触神经传递、情绪行为和其他大脑功能的调节中发挥重要作用。 | |||
T61463 | |||
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a potent dual inhibitor of monoamine oxidase (MAO) and aromatase, with IC50 values of 39 nM and 31 nM for MAO-B and aromatase, respectively. It holds significant potential for research in neurological disorders and breast cancer [1]. | |||
T60806 | |||
Monoamine Oxidase B inhibitor 2 是有可逆并且口服有效的和选择性的单胺氧化酶 B (MAO-B) 抑制剂(IC50 = 1.33 nM) ,可以透过血脑屏障 (BBB)。Monoamine Oxidase B inhibitor 2 显示出抗氧化和抗神经炎症活性,可用于研究帕金森病。 | |||
T8849 | MAO | ||
PF-9601N 是一种单胺氧化酶 B (MAO-B) 抑制剂,在多种体内外模型中表现出抗帕金森病 (PD) 的神经保护作用。它可用于研究兴奋性毒性介导的神经退行性疾病。 | |||
T60656 | |||
Monoamine Oxidase B inhibitor 1 是一种可逆、口服有效和选择性的单胺氧化酶 B 抑制剂 (IC50 = 0.02 nM),可以穿过血脑屏障 (BBB)。Monoamine Oxidase B inhibitor 1 显示出抗氧化和抗神经炎症活性,可用于研究帕金森病。 | |||
T0235 | MAO Monoamine Oxidase | ||
Modaline sulfate 是一种 MAO 抑制剂,用于研究抑郁症。 | |||
T4559 | Monoamine Oxidase | ||
Isocarboxazid 是不可逆的、非选择性的单胺氧化酶 monoamine oxidase 抑制剂,其在大鼠大脑中测得的 IC50值为4.8 μM。 | |||
T22605 | MAO Monoamine Oxidase | ||
Bifemelane hydrochloride 是一种选择性的,有效的,和竞争性的单胺氧化酶A (MAO-A)抑制剂,Ki=4.20 μM,它也非竞争性地抑制MAO-B,Ki=46.0 μM。它具有显著的抗抑郁作用,可用于研究与脑血管疾病有关的认知和情绪障碍。 | |||
TN1120 | MAO Monoamine Oxidase | ||
Osthenol 是一种前酰化香豆素,从独活干根中分离得到。它对重组 hMAO-A 具有潜在的选择性抑制作用,IC50=0.74 µM,对 hMAO-A 和 hMAO-B 表现出较高的选择性指数。它是一种可逆的,选择性的竞争性人单胺氧化酶-A(hMAO-A)抑制剂 (Ki=0.26 µM)。 | |||
T7147 | Monoamine Transporter | ||
Valbenazine (NBI-98854) 是一种高度选择性的囊泡单胺转运蛋白 2 (VMAT2) 抑制剂,Ki 为 110-190 nM,用于治疗迟发性运动障碍。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPJ-00379 | AOC3 Protein, Human, Recombinant (hFc) | Human | Human Cells | ||
Membrane primary amine oxidase(AOC3), also known as vascular adhesion protein (VAP-1) and HPAO, this protein is a member of the semicarbazide-sensitive amine oxidase (SSAO) family. VAP-1 is a type 1 membrane-bound glycoprotein that has a distal adhesion domain and an enzymatically active amine oxidase site outside of the membrane, VAP-1 has adhesive properties, functional monoamine oxidase activity, and possibly plays a role in glucose handling, leukocyte trafficking, and migration during inflammation. This rise in metabolic products contributes to generating advanced glycation end-products and oxidative stress along with the monoamine detoxification in the organism. It is highly expressed on the endothelium of the lung and trachea, and absent from leukocytes and epithelial cells. Membrane-bound VAP-1 releases an active, soluble form of the protein, which may be conducive to increased inflammation and the progression of many vascular disorders. In particular, elevation of VAP-1 activity and the increased enzymatic-mediated deamination is proposed to play a role in renal and vascular disease, oxidative stress, acute and chronic hyperglycemia, and diabetes complications.
|
|||||
TMPY-00506 | GAPDH Protein, Mouse, Recombinant (His) | Mouse | E. coli | ||
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH or G3PDH) is an enzyme of about 37kDa that is consisdered as a cellular enzyme involved in glycolysis. It catelyzes the sixth step of glycolysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Its role as a mediator for cell death has also been highlighted. A recent report suggests that GAPDH may be genetically associated with late-onset of Alzheimer's disease. Besides, deprenyl, which has originally been used as a monoamine oxidase inhibitor for Parkinson's disease, binds to GAPDH and displays neuroprotective actions.
|
|||||
TMPY-02446 | GAPDH Protein, Human, Recombinant (His) | Human | E. coli | ||
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH or G3PDH) is an enzyme of about 37kDa that is consisdered as a cellular enzyme involved in glycolysis. It catelyzes the sixth step of glycolysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Its role as a mediator for cell death has also been highlighted. A recent report suggests that GAPDH may be genetically associated with late-onset of Alzheimer's disease. Besides, deprenyl, which has originally been used as a monoamine oxidase inhibitor for Parkinson's disease, binds to GAPDH and displays neuroprotective actions.
|
|||||
TMPY-03056 | LSD1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus-Insect Cells | ||
LSD1 belongs to the flavin monoamine oxidase family. It contains 1 SWIRM domain and is a component of an RCOR/GFI/LSD1/HDAC complex. LSD1 interacts directly with GFI1 and GFI1B. LSD1 specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 through a FAD-dependent oxidative reaction. When forming a complex with an androgen receptor (and possibly other nuclear hormone receptors), LSD1 changes its substrates to H3K9me2. Thus LSD1 is considered to act as a coactivator or a corepressor. It may play a role in the repression of neuronal genes. Alone, LSD1 is unable to demethylate H3 'Lys-4' on nucleosomes and requires the presence of RCOR1/CoREST to achieve such activity.
|